Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spectral Diagnostics Inc. (EDTXF : OTC)

• Company Description    Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $1.04 Daily Weekly Monthly 20 Day Moving Average: 11,283 shares Shares Outstanding: 292.55 (millions) Market Capitalization: $304.25 (millions) Beta: 0.07 52 Week High: $1.27 52 Week Low: $0.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.20% 13.40% 12 Week 1.04% -0.59% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 135 The West Mall Unit 2 - Toronto,A6 M9C 1C2 CAN ph: 416-626-3233 fax: 416-626-7383 am@spinnakercmi.com https://spectraldx.com

• General Corporate Information    Officers Chris Seto - Chief Executive Officer Anthony Bihl - Chairman of the Board Debra M. Foster - Vice President Paul Walker - Director William Stevens - Director Peer Information Spectral Diagnostics Inc. (ABMD) Spectral Diagnostics Inc. (DMDS) Spectral Diagnostics Inc. (CPWY.) Spectral Diagnostics Inc. (EQUR) Spectral Diagnostics Inc. (ECIA) Spectral Diagnostics Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 847577103 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 292.55 Most Recent Split Date: (:1) Beta: 0.07 Market Capitalization: $304.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 157.07 EPS Growth vs. Year Ago Period: -166.67% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 33.15% vs. Previous Quarter: -16.67% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -718.77 06/30/25 - -361.73 Current Ratio 12/31/25 - - 09/30/25 - 0.11 06/30/25 - 0.12 Quick Ratio 12/31/25 - - 09/30/25 - 0.10 06/30/25 - 0.11 Operating Margin 12/31/25 - - 09/30/25 - -1,538.46 06/30/25 - -832.62 Net Margin 12/31/25 - - 09/30/25 - -1,538.72 06/30/25 - -832.89 Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,537.94 06/30/25 - -832.51 Book Value 12/31/25 - - 09/30/25 - -0.17 06/30/25 - -0.10 Inventory Turnover 12/31/25 - - 09/30/25 - 5.02 06/30/25 - 4.40 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©